annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
1043880082 | rs1042597 | rs1042597 | UGT1A8 | CC | 3 | Toxicity | cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus | Kidney Transplantation | Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genet... | https://www.clinpgx.org/clinicalAnnotation/1043880082 |
1043880082 | rs1042597 | rs1042597 | UGT1A8 | CG | 3 | Toxicity | cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus | Kidney Transplantation | Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other geneti... | https://www.clinpgx.org/clinicalAnnotation/1043880082 |
1043880082 | rs1042597 | rs1042597 | UGT1A8 | GG | 3 | Toxicity | cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus | Kidney Transplantation | Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other geneti... | https://www.clinpgx.org/clinicalAnnotation/1043880082 |
1043880098 | rs7311358 | rs7311358 | SLCO1B3 | AA | 3 | Other | mycophenolate mofetil | Kidney Transplantation | Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. | https://www.clinpgx.org/clinicalAnnotation/1043880098 |
1043880098 | rs7311358 | rs7311358 | SLCO1B3 | AG | 3 | Other | mycophenolate mofetil | Kidney Transplantation | Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. | https://www.clinpgx.org/clinicalAnnotation/1043880098 |
1043880098 | rs7311358 | rs7311358 | SLCO1B3 | GG | 3 | Other | mycophenolate mofetil | Kidney Transplantation | Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil. | https://www.clinpgx.org/clinicalAnnotation/1043880098 |
1043880143 | rs708272 | rs708272 | CETP | AA | 3 | Efficacy | HMG-CoA reductase inhibitors | Coronary Artery Disease | Patients with the rs708272 AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880143 |
1043880143 | rs708272 | rs708272 | CETP | AG | 3 | Efficacy | HMG-CoA reductase inhibitors | Coronary Artery Disease | Patients with the rs708272 AG genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype, or may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/1043880143 |
1043880143 | rs708272 | rs708272 | CETP | GG | 3 | Efficacy | HMG-CoA reductase inhibitors | Coronary Artery Disease | Patients with the rs708272 GG genotype and Coronary Artery Disease who are treated with statins may have less of a reduction in cardiovascular events as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880143 |
1043880165 | rs4680 | rs4680 | COMT | AA | 3 | Efficacy | venlafaxine | Anxiety Disorders;Depressive Disorder | Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1043880165 |
1043880165 | rs4680 | rs4680 | COMT | AG | 3 | Efficacy | venlafaxine | Anxiety Disorders;Depressive Disorder | Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1043880165 |
1043880165 | rs4680 | rs4680 | COMT | GG | 3 | Efficacy | venlafaxine | Anxiety Disorders;Depressive Disorder | Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype, although this has been contradicted in some studies. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1043880165 |
1043880170 | rs708272 | rs708272 | CETP | AA | 4 | Efficacy | simvastatin | Hypercholesterolemia;Hyperlipoproteinemia Type II | Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a... | https://www.clinpgx.org/clinicalAnnotation/1043880170 |
1043880170 | rs708272 | rs708272 | CETP | AG | 4 | Efficacy | simvastatin | Hypercholesterolemia;Hyperlipoproteinemia Type II | Patients with the AG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patien... | https://www.clinpgx.org/clinicalAnnotation/1043880170 |
1043880170 | rs708272 | rs708272 | CETP | GG | 4 | Efficacy | simvastatin | Hypercholesterolemia;Hyperlipoproteinemia Type II | Patients with the GG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patien... | https://www.clinpgx.org/clinicalAnnotation/1043880170 |
1043880192 | rs708272 | rs708272 | CETP | AA | 4 | Efficacy;Toxicity | atorvastatin | null | Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and... | https://www.clinpgx.org/clinicalAnnotation/1043880192 |
1043880192 | rs708272 | rs708272 | CETP | AG | 4 | Efficacy;Toxicity | atorvastatin | null | Patients with the AG genotype who are treated with atorvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a ... | https://www.clinpgx.org/clinicalAnnotation/1043880192 |
1043880192 | rs708272 | rs708272 | CETP | GG | 4 | Efficacy;Toxicity | atorvastatin | null | Patients with the GG genotype who are treated with atorvastatin may have an increased response to treatment and a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and... | https://www.clinpgx.org/clinicalAnnotation/1043880192 |
1043880205 | rs708272 | rs708272 | CETP | AA | 3 | Efficacy | lovastatin | null | Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880205 |
1043880205 | rs708272 | rs708272 | CETP | AG | 3 | Efficacy | lovastatin | null | Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880205 |
1043880205 | rs708272 | rs708272 | CETP | GG | 3 | Efficacy | lovastatin | null | Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880205 |
1043880214 | rs35068180 | rs35068180 | MMP3 | A/del | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the A/del genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880214 |
1043880214 | rs35068180 | rs35068180 | MMP3 | AA | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880214 |
1043880214 | rs35068180 | rs35068180 | MMP3 | del/del | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the del/del genotype and Coronary Artery Disease may be less likely to benefit from pravastatin treatment as compared to patients with the AA or A/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880214 |
1043880229 | rs35068180 | rs35068180 | MMP3 | A/del | 3 | Efficacy | chlorthalidone;lisinopril | Hypertension | Patients with the A/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke. | https://www.clinpgx.org/clinicalAnnotation/1043880229 |
1043880229 | rs35068180 | rs35068180 | MMP3 | AA | 3 | Efficacy | chlorthalidone;lisinopril | Hypertension | Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke. | https://www.clinpgx.org/clinicalAnnotation/1043880229 |
1043880229 | rs35068180 | rs35068180 | MMP3 | del/del | 3 | Efficacy | chlorthalidone;lisinopril | Hypertension | Patients with the del/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke. | https://www.clinpgx.org/clinicalAnnotation/1043880229 |
1043880234 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | fluvastatin | Coronary Artery Disease | Patients with the insert/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del/del or del/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880234 |
1043880234 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | fluvastatin | Coronary Artery Disease | Patients with the del/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del/del genotype, or may have a better response to fluvastatin treatment as compared to patients with the insert/insert genotype. Other genetic and clinical factors may also... | https://www.clinpgx.org/clinicalAnnotation/1043880234 |
1043880234 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | fluvastatin | Coronary Artery Disease | Patients with the del/del genotype and Coronary Artery Disease may have a better response to fluvastatin treatment as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880234 |
1043880255 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | pravastatin | null | Patients with the insert/insert genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880255 |
1043880255 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | pravastatin | null | Patients with the insert/del genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880255 |
1043880255 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | pravastatin | null | Patients with the del/del genotype may be more likely to benefit from pravastatin treatment as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880255 |
1043880276 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | atorvastatin;quinapril | Coronary Artery Disease | Patients with the insert/insert genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due to an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patie... | https://www.clinpgx.org/clinicalAnnotation/1043880276 |
1043880276 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | atorvastatin;quinapril | Coronary Artery Disease | Patients with the insert/del genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's r... | https://www.clinpgx.org/clinicalAnnotation/1043880276 |
1043880276 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | atorvastatin;quinapril | Coronary Artery Disease | Patients with the del/del genotype and Coronary Artery Disease may benefit less from atorvastatin and quinapril treatment (due to less of a reduction in the fibrinolytic marker D-dimer) as compared to patients with the insert/del or insert/insert genotype. Other genetic and clinical factors may also influence a patient... | https://www.clinpgx.org/clinicalAnnotation/1043880276 |
1043880293 | rs3211371 | rs3211371 | CYP2B6 | CC | 3 | Toxicity | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may a... | https://www.clinpgx.org/clinicalAnnotation/1043880293 |
1043880293 | rs3211371 | rs3211371 | CYP2B6 | TC | 3 | Toxicity | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also in... | https://www.clinpgx.org/clinicalAnnotation/1043880293 |
1043880293 | rs3211371 | rs3211371 | CYP2B6 | TT | 3 | Toxicity | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also in... | https://www.clinpgx.org/clinicalAnnotation/1043880293 |
1043880298 | rs12721655 | rs12721655 | CYP2B6 | AA | 3 | Efficacy | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic fact... | https://www.clinpgx.org/clinicalAnnotation/1043880298 |
1043880298 | rs12721655 | rs12721655 | CYP2B6 | AG | 3 | Efficacy | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors ma... | https://www.clinpgx.org/clinicalAnnotation/1043880298 |
1043880298 | rs12721655 | rs12721655 | CYP2B6 | GG | 3 | Efficacy | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors ma... | https://www.clinpgx.org/clinicalAnnotation/1043880298 |
1043880303 | rs12720462 | rs12720462 | FMO1 | AA | 3 | Other | olanzapine | null | Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880303 |
1043880303 | rs12720462 | rs12720462 | FMO1 | AC | 3 | Other | olanzapine | null | Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880303 |
1043880303 | rs12720462 | rs12720462 | FMO1 | CC | 3 | Other | olanzapine | null | Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880303 |
1043880308 | rs2266780 | rs2266780 | FMO3 | AA | 3 | Other | olanzapine | null | Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880308 |
1043880308 | rs2266780 | rs2266780 | FMO3 | AG | 3 | Other | olanzapine | null | Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880308 |
1043880308 | rs2266780 | rs2266780 | FMO3 | GG | 3 | Other | olanzapine | null | Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880308 |
1043880313 | rs7877 | rs7877 | FMO1 | CC | 3 | Other | olanzapine | null | Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880313 |
1043880313 | rs7877 | rs7877 | FMO1 | CT | 3 | Other | olanzapine | null | Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880313 |
1043880313 | rs7877 | rs7877 | FMO1 | TT | 3 | Other | olanzapine | null | Patients with TT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880313 |
1043880318 | rs735482 | rs735482 | ERCC1 | AA | 3 | Efficacy | thalidomide | Multiple Myeloma | Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880318 |
1043880318 | rs735482 | rs735482 | ERCC1 | AC | 3 | Efficacy | thalidomide | Multiple Myeloma | Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880318 |
1043880318 | rs735482 | rs735482 | ERCC1 | CC | 3 | Efficacy | thalidomide | Multiple Myeloma | Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880318 |
1043880323 | rs1051685 | rs1051685 | XRCC5 | AA | 3 | Efficacy | thalidomide | Multiple Myeloma | Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880323 |
1043880323 | rs1051685 | rs1051685 | XRCC5 | AG | 3 | Efficacy | thalidomide | Multiple Myeloma | Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880323 |
1043880323 | rs1051685 | rs1051685 | XRCC5 | GG | 3 | Efficacy | thalidomide | Multiple Myeloma | Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880323 |
1043880328 | rs4630 | rs4630 | GSTT1 | AA | 3 | Toxicity | thalidomide | Multiple Myeloma | Patients with the AA genotype may have increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880328 |
1043880328 | rs4630 | rs4630 | GSTT1 | AG | 3 | Toxicity | thalidomide | Multiple Myeloma | Patients with the AG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880328 |
1043880328 | rs4630 | rs4630 | GSTT1 | GG | 3 | Toxicity | thalidomide | Multiple Myeloma | Patients with the GG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide. | https://www.clinpgx.org/clinicalAnnotation/1043880328 |
1043880337 | rs10509680 | rs10509680 | CYP2C9 | GG | 3 | Dosage | warfarin | null | Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin. | https://www.clinpgx.org/clinicalAnnotation/1043880337 |
1043880337 | rs10509680 | rs10509680 | CYP2C9 | TG | 3 | Dosage | warfarin | null | Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin. | https://www.clinpgx.org/clinicalAnnotation/1043880337 |
1043880337 | rs10509680 | rs10509680 | CYP2C9 | TT | 3 | Dosage | warfarin | null | Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin. | https://www.clinpgx.org/clinicalAnnotation/1043880337 |
1043880357 | rs11150606 | rs11150606 | VKORC1 | CC | 3 | Dosage | warfarin | null | Patients with the rs11150606 CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880357 |
1043880357 | rs11150606 | rs11150606 | VKORC1 | CT | 3 | Dosage | warfarin | null | Patients with the rs11150606 CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880357 |
1043880357 | rs11150606 | rs11150606 | VKORC1 | TT | 3 | Dosage | warfarin | null | Patients with the rs11150606 TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880357 |
1043880362 | rs17886199 | rs17886199 | PRSS53;VKORC1 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880362 |
1043880362 | rs17886199 | rs17886199 | PRSS53;VKORC1 | AG | 3 | Dosage | warfarin | null | Patients with the AG genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880362 |
1043880362 | rs17886199 | rs17886199 | PRSS53;VKORC1 | GG | 3 | Dosage | warfarin | null | Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880362 |
1043880367 | rs1800566 | rs1800566 | NQO1 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880367 |
1043880367 | rs1800566 | rs1800566 | NQO1 | AG | 3 | Dosage | warfarin | null | Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880367 |
1043880367 | rs1800566 | rs1800566 | NQO1 | GG | 3 | Dosage | warfarin | null | Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880367 |
1043880392 | rs4918758 | rs4918758 | CYP2C9 | CC | 3 | Dosage | warfarin | null | Patients with the CC genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880392 |
1043880392 | rs4918758 | rs4918758 | CYP2C9 | CT | 3 | Dosage | warfarin | null | Patients with the CT genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880392 |
1043880392 | rs4918758 | rs4918758 | CYP2C9 | TT | 3 | Dosage | warfarin | null | Patients with the TT genotype may require increased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880392 |
1043880397 | rs4917639 | rs4917639 | CYP2C9 | AA | 3 | Dosage | warfarin | null | Patients with the rs4917639 AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880397 |
1043880397 | rs4917639 | rs4917639 | CYP2C9 | CA | 3 | Dosage | warfarin | null | Patients with the rs4917639 CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880397 |
1043880397 | rs4917639 | rs4917639 | CYP2C9 | CC | 3 | Dosage | warfarin | null | Patients with the rs4917639 CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880397 |
1043880402 | rs61162043 | rs61162043 | VKORC1 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880402 |
1043880402 | rs61162043 | rs61162043 | VKORC1 | AG | 3 | Dosage | warfarin | null | Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880402 |
1043880402 | rs61162043 | rs61162043 | VKORC1 | GG | 3 | Dosage | warfarin | null | Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/1043880402 |
1043880409 | rs60282872 | rs60282872 | SREBF1 | C/del | 3 | Efficacy | fluvastatin | null | Patients with the CC/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels as compared to patients with the C/C genotype, or may have a larger change in apolipoprotein A1 and C3 levels as compared to patients with the del/del genotype. Changes with treatment in other... | https://www.clinpgx.org/clinicalAnnotation/1043880409 |
1043880409 | rs60282872 | rs60282872 | SREBF1 | CC | 3 | Efficacy | fluvastatin | null | Patients with the CC genotype who are treated with fluvastatin may have a larger change in apolipoprotein A1 and C3 levels, as compared to patients with the C/del or del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also i... | https://www.clinpgx.org/clinicalAnnotation/1043880409 |
1043880409 | rs60282872 | rs60282872 | SREBF1 | del/del | 3 | Efficacy | fluvastatin | null | Patients with the del/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels, as compared to patients with the CC or C/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also ... | https://www.clinpgx.org/clinicalAnnotation/1043880409 |
1043880426 | rs12487736 | rs12487736 | SCAP | CC | 3 | Efficacy | simvastatin | Hypercholesterolemia | Patients with the CC genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880426 |
1043880426 | rs12487736 | rs12487736 | SCAP | CT | 3 | Efficacy | simvastatin | Hypercholesterolemia | Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880426 |
1043880426 | rs12487736 | rs12487736 | SCAP | TT | 3 | Efficacy | simvastatin | Hypercholesterolemia | Patients with the TT genotype and Hypercholesterolemia may have a reduced response to simvastatin treatment as compared to patients with the the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880426 |
1043880433 | rs12487736 | rs12487736 | SCAP | CC | 4 | Other | atorvastatin | null | Patients with the CC genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880433 |
1043880433 | rs12487736 | rs12487736 | SCAP | CT | 4 | Other | atorvastatin | null | Patients with the CT genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880433 |
1043880433 | rs12487736 | rs12487736 | SCAP | TT | 4 | Other | atorvastatin | null | Patients with the TT genotype who are treated with atorvastatin may have reduced expression of SCAP as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880433 |
1043880438 | rs6755571 | rs6755571 | UGT1A4 | AA | 3 | Other | ABT-751 | Neoplasms | Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880438 |
1043880438 | rs6755571 | rs6755571 | UGT1A4 | AC | 3 | Other | ABT-751 | Neoplasms | Patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880438 |
1043880438 | rs6755571 | rs6755571 | UGT1A4 | CC | 3 | Other | ABT-751 | Neoplasms | Patients with the CC genotype and neoplasms may have an increased plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880438 |
1043880447 | rs8016905 | rs8016905 | BDKRB2 | AA | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzy... | https://www.clinpgx.org/clinicalAnnotation/1043880447 |
1043880447 | rs8016905 | rs8016905 | BDKRB2 | AG | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibit... | https://www.clinpgx.org/clinicalAnnotation/1043880447 |
1043880447 | rs8016905 | rs8016905 | BDKRB2 | GG | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzy... | https://www.clinpgx.org/clinicalAnnotation/1043880447 |
1043880454 | rs4986790 | rs4986790 | TLR4 | AA | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic ... | https://www.clinpgx.org/clinicalAnnotation/1043880454 |
1043880454 | rs4986790 | rs4986790 | TLR4 | AG | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/1043880454 |
1043880454 | rs4986790 | rs4986790 | TLR4 | GG | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and... | https://www.clinpgx.org/clinicalAnnotation/1043880454 |
1043880467 | rs4986790 | rs4986790 | TLR4 | AA | 3 | Toxicity | folic acid;methotrexate | Rheumatoid arthritis | Patients with the AA genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880467 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.